Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Silence Therapeutics PLC Sponsored ADR (SLN) had Return on Tangible Equity of -43.96% for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-12.27M |
|
-- |
|
-- |
|
$13.87M |
|
$-13.87M |
|
$1.60M |
|
$-12.27M |
|
$-12.27M |
|
$-12.27M |
|
$-12.27M |
|
$-12.27M |
|
$-12.27M |
|
$-13.87M |
|
$-13.76M |
|
47.24M |
|
47.24M |
|
$-0.26 |
|
$-0.26 |
|
| Balance Sheet Financials | |
$94.28M |
|
$1.32M |
|
$12.13M |
|
$106.41M |
|
$12.71M |
|
-- |
|
$55.23M |
|
$67.94M |
|
$38.47M |
|
$27.91M |
|
$38.47M |
|
47.25M |
|
| Cash Flow Statement Financials | |
$-14.09M |
|
$74.94M |
|
$0.00M |
|
$11.28M |
|
$72.05M |
|
$60.78M |
|
$3.75M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.42 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-14.09M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-31.89% |
|
|
Return on Tangible Equity |
-43.96% |
-11.53% |
|
-31.89% |
|
$0.81 |
|
$-0.30 |
|
$-0.30 |
|